Swiss pharma companies warn current pricing rules delay access to new medicines.
Pharma companies have said they will not launch drugs in Switzerland if the prices are too low.
Keystone / Gaetan Bally
Interpharma, the association of research-based pharmaceutical companies in Switzerland, believes that access to innovative medicines is worsening since the US introduced policies to lower drug prices in line with peer countries.
Generated with artificial intelligence.
This content was published on
Interpharma warns Switzerland may face a US Section 301 trade probe targeting drug pricing, threatening $35.5 billion in pharma…
Trump puts pressure on Swiss companies to raise pharma prices in Europe
The need for clarity on Swedish pricing and reimbursement has put new medicine launches on hold
Debates over drug pricing have prompted Swissinfo readers to ask whether pharma companies can set prices for new drugs as high as…
To tackle medicine shortages, the Swiss government intends to make it easier to import and manufacture medicines.
The claims from pharmaceutical giant Novartis comes amid a row over drug pricing deals.
